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Abstract
Thyroid hormones (TH) are involved in a wide variety of biological processes, including neurodevelopment, regulation of intermediary 
metabolism, and energy expenditure. TH actively participate in basal energy expenditure and adaptive thermogenesis, and for this reason 
body weight can be affected during dysthyroidism. Obesity is a non-transmissible, chronic, inflammatory, metabolic disease that implies 
a positive energy balance. The adipose tissue produces a series of hormones and adipocytokines such as leptin, which can influence the 
thyroid status at different levels. There is evidence showing that thyroid dysfunction could predispose to obesity; conversely, there is also 
evidence suggesting that obesity induces thyroidal alterations. The aim of this review is to describe the relation between the thyroidal 
system and obesity; in addition, we present a hypothetical model highlighting the importance of TH peripheral deiodination and its role 
in the establishment of a positive energy balance. We conclude that the relation between the thyroid system and obesity and overweight 
is complex and involves multiple levels of interaction. In addition, the assessment of the obese patient should consider an evaluation of 
the thyroidal function in order to achieve a better and personalised treatment for these patients. (Endokrynol Pol 2018; 69 (3): 292–303)
Key words: thyroid hormone metabolism, obesity, iodothyronine deiodinases, thermogenesis, energy balance
Streszczenie
Hormony tarczycy (thyroid hormones, TH) są zaangażowane w wiele różnych procesów biologicznych, wliczając rozwój układu nerwowego, 
regulację metabolizmu pośredniego oraz zużycie energii. Aktywnie uczestniczą w podstawowym zużyciu energii i termogenezie 
adaptacyjnej i z tego względu mogą mieć wpływ na masę ciała w przebiegu chorób tarczycy. Otyłość to niezakaźna, przewlekła, zapalna 
choroba metaboliczna, która implikuje dodatni bilans energetyczny. Tkanka tłuszczowa produkuje szereg hormonów i adipocytokin, 
takich jak leptyna, które mogą wpływać na stan tarczycy na różnych poziomach. Istnieją dowody na to, że dysfunkcja tarczycy może 
predysponować do otyłości i odwrotnie, istnieją dowody sugerujące, że otyłość powoduje zmiany dotyczące tarczycy. Celem tej pracy 
było opisanie związku między układem tarczycy a otyłością. Ponadto w pracy zaprezentowano hipotetyczny model podkreślający 
znaczenie obwodowej dejodynacji hormonów tarczycy i jego rolę w ustanowieniu dodatniego bilansu energetycznego. Podsumowując, 
możemy stwierdzić, że relacja między układem tarczycy a otyłością i nadwagą jest złożona i obejmuje wiele poziomów interakcji. Ponadto, 
poddając ocenie otyłego pacjenta, powinno się rozważyć ocenę funkcji tarczycy, aby uzyskać lepsze i spersonalizowane efekty leczenia. 
(Endokrynol Pol 2018; 69 (3): 292–303)
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Abbreviations
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T4: thyroxine
T3: triiodothyronine
TSH: thyrotropin
TRH: thyrotropin-releasing hormone
TR: thyroid hormone receptor
HPT axis: hypothalamic-pituitary-thyroid axis
NR: nuclear receptor
Ds: iodothyronine deiodinases
D1: iodothyronine deiodinase type 1
D2: iodothyronine deiodinase type 2
UCP1: uncoupling protein type 1
ASNS: autonomic sympathetic nervous system
BMI: body mass index
Introduction
Thyroid hormones (TH) participate in the regulation 
of most of the cellular processes, like growth and de-
velopment, intermediary metabolism, and neurode-
velopment, among others. TH are key regulators of 
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energy balance, and this is reflected in the associated 
alterations in patients with hypo- and hyperthyroid-
ism. TH metabolism is complex and depends on the 
peripheral deiodination of the pro-hormone T4 to T3, 
which is the main bioactive hormone [1]. On the other 
hand, obesity is the most prevalent metabolic disease 
worldwide and it is a major health issue consider-
ing the associated comorbidities like hypertension, 
type 2 diabetes mellitus, dyslipidaemia, and cancer, 
among others [2]. Obesity is a disease with multiple 
alterations at the endocrine and immune levels, 
where hormones like leptin and adipocytokines play 
a significant role.
TH metabolic effects are strongly related to the 
mechanisms regulating body weight balance and 
body fat mass, by stimulating thermogenesis, lipid 
catabolism, and heat production [3]. One of the main 
target tissues of TH are adipocytes; therefore, obesity 
is strongly related to TH metabolism. In this context, 
there are several studies suggesting that a thyroidal 
dysfunction could predispose to obesity. Conversely, 
there is also evidence showing that obesity could lead 
to a thyroidal dysfunction. Considering this informa-
tion, this review analyses the relation and mechanisms 
involved between thyroidal physiology and obesity.
Thyroid hormones
Thyroid gland
The thyroid gland is one of the body’s largest endocrine 
organs, and one of the most richly vascularised tissues 
with the greatest blood flow in the human body. This 
is probably a reflection of the metabolic and functional 
relevance of this tissue, an exclusive site of production of 
TH, which participate in the morphogenesis and func-
tional maturation of virtually all tissues of the body, being 
crucial in the central and peripheral nervous system [1].
The basic functional units of the thyroid gland are 
the thyroid follicles — spherical structures composed 
of a simple cubic epithelium of specialised cells called 
thyrocytes. This spherical arrangement defines a central 
follicular cavity where the thyroid colloid is stored [4]. 
Significant amounts of iodine, an essential component 
of TH, are found within the thyroid colloid. The intrag-
landular deposit of TH is dependent on the thyroid 
functional status and dietary intake of iodine, and it 
is considered that this hormonal store is sufficient to 
protect the organism for an approximate period of up 
to three months, in a scenario of sudden cessation in 
the intake of iodine [1, 4]. The thyroid can concentrate 
iodine on average 40 times more compared to the levels 
found in plasma, making it the main body store of the 
halogen in the body [1].
Structure of TH
TH are essential during critical periods of the develop-
ment and differentiation of a large number of organs 
and systems, and participate in processes such as body 
growth, neurodevelopment, differentiation, and ther-
mogenesis [4–6]. Also, during adulthood TH are one of 
the main endocrine regulators of energy expenditure 
[1, 6].
TH are formed by two rings derived from the amino 
acid tyrosine (Figure 1) and are synthesised in the 
thyroid gland, through the iodination of the tyrosine 
residues present in the structure of the glycoprotein 
thyroglobulin, which acts as a template in the process 
of hormone synthesis [1, 5, 6].
TH synthesis is regulated by the hypothalamic- 
-pituitary-thyroid axis (HPT axis) through complex 
interactions that include the thyrotropin-releasing 
hormone (TRH) secreted by the paraventricular nu-
cleus of the hypothalamus, and the thyroid-stimulating 
hormone (TSH) secreted by the pituitary thyrotrophic 
cells [4, 7]. The increase in TH circulating concentra-
tions inhibits TRH and TSH production and release, 
an effect known as negative feedback. In contrast, 
a decrease in TH circulating levels eliminates the inhibi-
tory signals, reactivating TRH and TSH synthesis and 
release, and consequently the production of TH by the 
thyrocytes [7].
TH receptors
TH induces its biological effects through receptor-medi-
ated genomic mechanisms, which belong to the nuclear 
receptor superfamily (NR). NR are ligand-dependent 
transcription factors that are functionally divided into 
six structural domains called A to F (Figure 2A) [8]. The 
A/B domain is susceptible to post-translational modi-
fications, while the C domain allows interaction with 
DNA. The D domain possesses the “hinge” function, 
and the E domain is the binding site of the ligand and 
co-regulatory proteins. The F domain corresponds to 
a variable region at the C-terminal end involved in re-
ceptor activation. The C domain binds to DNA through 
a zinc finger structural motif, which recognises specific 
hexanucleotide sequences termed thyroid hormone 
responsive elements. The binding of TH to the recep-
tor induces conformational changes in the protein that 
favour the interaction with coactivating proteins or 
corepressors, which modulates the transcriptional ef-
fect of TH [8]. T4 is considered a prohormone because 
it is 3-4 times less potent than T3, considered the main 
bioactive TH, and because most of the circulating T3 is 
generated at the peripheral level by enzymatic deio-
dination of T4 (its circulating levels are approximately 
40 times higher than T3) [5].
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The THRA and THRB genes are located in the hu-
man chromosomes 17 and 3, respectively, and codify 
for the major TH receptors isoforms (TR): TRa1, TRb1, 
and TRb2 (Figure 2B) [9]. Each of these isoforms binds 
to T3 with similar affinity and mediates the genomic 
effects of TH [10, 11]. The TRb1 isoform predominates 
systemically, with greater expression in hepatic tissue, 
brain, retina, inner ear, kidney, and adipose tissue [8, 12]. 
The TRb1 isoform is also widely distributed in all tissues, 
especially heart, where its expression is responsible for 
changes in heart rate and frequency, as well as in brain 
and skeletal muscle [8]. TRb2 expression is limited to 
the anterior region of the pituitary and hypothalamus, 
where it acts as the major regulator of the negative feed-
back of the HPT axis [8]. The expression of TR and that 
of multiple TH-dependent genes is regulated by T3 in 
a specific tissue manner (Table I) [13, 14]. Therefore, an 
area of recent interest is the study of selective agonists 
of the different TR subtypes with distinct potential 
therapeutic actions [15].
TH deiodination
As previously mentioned, T4 circulating levels are high-
er than those of T3, because the thyroid gland secretes 
mainly T4 and much less T3, in an approximate ratio 
of 6 to 1. However, it is considered that on average 80% 
of the circulating T3 comes directly from the enzymatic 
deiodination of T4 at the peripheral level. The deiodina-
tion is catalysed by a group of isoenzymes generically 
known as iodothyronine deiodinases (Ds). Three 
isotypes of Ds are known: D1, D2, and D3, which are 
integral membrane enzymes with punctual differences 
between them, such as their subcellular localisation, 
preferred substrates, and generated products — which 
explains their functional differences [5, 6]. Ds regulate 
the bioavailability of active/inactive TH at the peripheral 
level and are currently considered an extension of the 
HPT axis (Figure 2C).
TH, leptin, and weight regulation
The basal metabolic rate has long been used as an 
indicator of thyroid status [3]. The thyroid profile is 
also one of the most requested paraclinical exams in 
medical practice, especially due to the insistence of 
patients entering the clinic attributing the cause of its 
weight gain due to a thyroid malfunction [4]. One of 
the main regulators of appetite and weight gain is lep-
tin, a protein hormone secreted by adipocytes, whose 
circulating concentration increases in relation to body 
fat mass. Among other tissues, leptin acts in the hypo-
thalamus, where it regulates food intake and energy 
expenditure [16]. Interestingly, TSH synthesis by thy-
rotropes has been reported to increase due to the exog-
enous administration of leptin in a murine model [17]. 
The action of leptin is carried out mainly in the arcuate 
nucleus of the hypothalamus, but also through other 
regions of the brain such as the brain stem, the fourth 
ventricle, and the vagal dorsal complex, all innervating 
Common name Symbol Substituents Systematic name
R3 R3 R5 R5
Thyroxine T4 I I I I 3,3´ ,5,5´ -Tetra-iodo-L-thyronine
Triiodothyronine T3 I I I H 3,3´ ,5,-Tri-iodo-L-thyronine
Reverse Triiodothyronine rT3 I I H I 3,3´ ,5´ -Tri-iodo-L-thyronine
3,5’-diiodothyronine 3,5-T2 I H I H 3,5-Di-iodo-L-thyronine
3,3’-diiodothyronine 3,3´-T2 I I H H 3,3´ -Di-iodo-L-thyronine
Figure 1. Chemical structure and nomenclature of the main TH. Upper part shows TH basic chemical structure composed by two rings 
of the amino acid tyrosine. The inner ring retains the amino and carboxyl groups (b-alanine chain), and the outer ring is bound to the 
inner one by an ether type bond. The figure shows the nomenclature used in relation to the substituents present in the 3, 5 and 3’, 5’ 
positions of the inner and outer rings; respectively. Where: I — iodine; H — hydrogen. Modified from Solís-S et al., 2011 [6]
Rycina 1. Struktura chemiczna i nazewnictwo głównych hormonów tarczycy. Górna część przedstawia podstawową strukturę chemiczną 
hormonów tarczycy, złożoną z dwóch pierścieni aminokwasu tyrozyny. Pierścień wewnętrzny zachowuje grupy aminową i karboksylową 
(łańcuch b-alaniny), natomiast zewnętrzny jest połączony z pierścieniem wewnętrznym wiązaniem eterowym. Na rycinie przedstawiono 
nazewnictwo używane w odniesieniu do podstawników obecnych w pozycjach 3, 5 i 3’, 5’ odpowiednio zewnętrznego i wewnętrznego 
pierścienia, gdzie: I — jod; H — wodór. Zmodyfikowano z Solís-S i wsp., 2011 [6]
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Figure 2. Structure of TH receptors (TR) and associated genomic mechanisms. Panel A: General scheme of nuclear receptors. The A/B 
domain is a hypervariable domain with transactivation functions, the C domain is the DNA binding region, the D domain contains the 
hinge. The E domain binds the ligand and has dimerisation sequences, and the F domain is a hypervariable transactivation domain. The 
amino (N) and carboxyl (C) terminal end of the protein are also shown. Panel B: Schematic representation of the main TH receptors. 
The TR have a high homology in the C domain (blank region) and D/E (grey region) domains. The A/B domain (dotted region) at the 
N-terminal end is variable in length. Numbers indicate the length in number of amino acids. Panel C: Simplified mechanism of TH 
action. TH enter the cell through membrane-specific transporters. The circulating T4 is intracellularly transformed by deiodinase type 2 
(D2) to the active form T3. Deiodinase type 3 (D3) transforms T4 into the inactive form rT3. Deiodinase type 1 (D1) can either activate 
or inactivate T4. At the nuclear level, in the absence of the hormone; the complex formed by the heterodimer: retinoic acid receptor (RXR) 
and TR (RXR-TR), binds to TH-response elements located in the DNA (TRE). The RXR-TR complex recruit corepressors proteins that 
will inhibit gene transcription. In the presence of T3, the binding of the ligand induces conformational modifications of the TR, which 
favours the displacement of corepressors and the recruitment of coactivators, which promote transcriptional machinery binding to DNA 
and the expression of the target genes. Modified from Cheng et al. 2010 [12] and Brent, 2012 [22]
Rycina 2. Struktura receptorów hormonów tarczycy (thyroid hormone receptors; TR) i powiązane z nimi mechanizmy genomowe. Panel A: 
Ogólny schemat receptorów jądrowych. Domena A/B jest domeną hiperzmienną z funkcją transaktywacyjną, domena C jest regionem 
wiążącym DNA, domena D zawiera zawias. Domena E wiąże ligand i umożliwia dimeryzację, a domena F jest domeną hiperzmienną 
z funkcją transaktywacyjną. Na rycinie przedstawiono również koniec aminowy (N) i karboksylowy (C) białka. Panel B: Schematyczne 
przedstawienie głównych receptorów hormonów tarczycy. Receptory hormonów tarczycy wykazują wysoką homologię w obrębie domeny 
C (pusty obszar) i domen D/E (obszar w kolorze szarym). Domena A/B (obszar wykropkowany) na końcu aminowym N ma zmienną 
długość. Liczby wskazują długość w ilości aminokwasów. Panel C: Uproszczony mechanizm działania hormonów tarczycy. Hormony 
tarczycy dostają się do komórki dzięki specyficznym błonowym transporterom. Krążący T4 jest przekształcany wewnątrzkomórkowo 
przez dejodynazę typu 2 (D2) do postaci aktywnej T3. Dejodynaza typu 3 (D3) przekształca T4 w nieaktywną postać rT3. Dejodynaza 
typu 1 (D1) może aktywować lub dezaktywować T4. Na poziomie jądrowym, w przypadku braku hormonu, kompleks utworzony 
przez heterodimer: receptor kwasu retinowego (retinoic acid receptor; RXR) i receptor hormonów tarczycy (RXR-TR) wiąże się ze 
specyficznymi dla hormonów tarczycy elementami odpowiedzi umiejscowionymi w DNA (thyroid hormone response elements, TRE). 
Kompleks RXR-TR rekrutuje białka hamujące, które zahamują transkrypcję genów. Wiązanie ligandu w obecności T3 indukuje zmiany 
konformacyjne receptorów hormonów tarczycy, co sprzyja przemieszczaniu się białek hamujących oraz rekrutowaniu koaktywatorów, 
które wspierają transkrypcyjny mechanizm wiązania z DNA oraz ekspresję genów docelowych. Zmodyfikowano z Cheng i wsp., 2010 
[12] i Brent, 2012 [22]
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the paraventricular nucleus through multi or monosyn-
aptic projections [16]. 
It is generally accepted that a positive energy ba-
lance (obese subjects) presents increased TSH and free 
T3 concentrations [18]. On the other hand, a negative 
energy balance in obese and thin humans inhibits the 
activity of the HPT, and gonadal and hypothalamus-
pituitary-somatotrope axis, while stimulating the 
adrenal axis [19]. An example of this relation can be 
found in anorexia nervosa, where some clinical mani-
festations of hypothyroidism such as bradycardia and 
hypothermia are present [19]. Thus, during periods of 
Table I. TH effects in mammals
Tabela I. Działanie hormonów tarczycy u ssaków
FUNCTION EFFECT REGULATED GENES
Thermogenesis ↑ glycolysis and oxygen consumption and synthesis of 
uncoupling proteins (UCP) in BAT
↑ UCP1, 2 and 3; Na/K ATPase 
(α and β subunits)
Vitamins Participate in vitamin A synthesis
↑ demand of other B complex components —
↓ thiamine phosphorylation
Growth and cellular 
differentiation
↑ somatic growth, maturation of the nervous system, 
and epiphyseal ossification
↑ GH
Central nervous system Essentials in development and neuronal growth. 
Modulate the speed of excitation and conduction and 
behaviour patterns.
↑ β5-tubulin; NGF; TrkA; RORα; CAMK-IV; PCP-2; 
COX-1; laminin; RC3; etc.
↓ tenascin C; NCAM; L1; SWAP; p75LNGFR; TOM 
M70A; α1 y β2 tubulin; etc.
Carbohydrates ↑ absorption & glucose oxidation, glycogenolysis and 
insulin degradation
↑ PEPCK; G6P; GLUT4
Heart Inotropic & chronotropic effect, synergism with 
catecholamines
↑ α-myosin (heavy chain); SERCA; β adrenergic 
receptors
↓ β-myosin (heavy chain)
Lipids ↑ synthesis, degradation and excretion of cholesterol 
and bile acids  
Modify the catecholamines response
↑ malic enzyme; S14 protein; carbonyl reductase; 
FATP
Haematopoiesis Participate in haemoglobin synthesis ↑ globin chain (α and β subunits)
Proteins Anabolism/catabolism —
Muscle ↓ conversion of creatine to phosphocreatine ↑ MBP
↓ actin; creatine kinase
Hydroelectrolytic metabolism ↑ glomerular filtration rate & sodium extracellular 
diuresis
↑ Na/K ATPase (α and β subunits); Na+/H+ 
interchanger
Hypothalamus/Pituitary Regulate TRH, TSH, GH, FSH, LH, and PRL synthesis 
and secretion
↑ GH
↓ TRH; TSH (α and β subunits); PRL
Reproductive system GONADS: needed for differentiation —
MAMMARY GLAND: essentials for the functional 
differentiation of the glandular primordium. Participate 
in the galactopoietic complex
Digestive system Modulate the gastrointestinal transit speed, increase 
vitamin B12 and folate absorption
↑ Na/K ATPase (α & β subunits); alkaline 
phosphatase
↓ lactase
Where: ↑ — increase or stimulation; ↓ — decrease or inhibition; TSH — thyroid-stimulating hormone; GH — growth hormone; FSH — follicle-stimulating hormone; 
LH — luteinizing hormone; PRL — prolactin; UCP — uncoupling protein; NGF — neural growth factor; TrkA — tropomyosin receptor kinase A; RORα — orphan 
nuclear receptor alpha; CAMK-IV — calcium/calmodulin-dependent protein kinase IV; PCP-2 — Purkinje cells type 2 protein; COX-1 — type 1 cyclooxygenase; RC3 
— neurogranin; NCAM — neural cell adhesion molecule; SWAP — suppressor-of-White-APricot splicing regulator; p75LNGFR — low affinity nerve growth factor 
receptor; TOM M70A — translocase of outer mitochondrial membrane 70; SERCA — sarco/endoplasmic reticulum Ca2+-ATPase; PEPCK — phosphoenolpyruvate 
carboxykinase; G6P — glucose-6-phosphatase; MBP — myosin binding protein; FATP — fatty-acid transport protein
*Modified from Solis-S et al., 2006 [4]
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starvation, serum leptin levels decrease, as do TH, TSH, 
and TRH concentrations [16]. In addition, it has been 
reported that TH increase the expression of leptin in 
adipocytes in vitro [20]. 
TH and intermediate metabolism
Basal metabolism or energy expenditure at rest is regu-
lated by TH and constitutes approximately two thirds 
(66%) of total daily energy expenditure [21–23]. In the 
absence of TH, basal energy expenditure would be re-
duced by more than 30%. The autonomic sympathetic 
nervous system (ASNS) and TH are the two main factors 
that directly influence energy expenditure at rest and 
glucose and lipid metabolism [1, 23].
T3 stimulates oxygen consumption in tissues by 
regulating proteins necessary for the synthesis and 
degradation of macronutrients, muscle contraction, and 
maintenance of transmembrane ionic gradients [8, 24]. It 
also modifies the function of mitochondria by affecting 
the composition of the membrane lipid and its protein 
components [8, 24]. The adipose tissue constitutes the 
main energetic store of the organism, and based on its 
histological and functional characteristics two main cell 
types of adipocytes are distinguished: white and brown. 
The main function of white adipose tissue (WAT) in 
humans is the storage, synthesis, and mobilisation of 
triglycerides. The main function of brown adipose tissue 
(BAT) is adaptive thermogenesis, a function that has 
recently undergone a metabolic rebirth by identifying 
its presence in adults [25]. Both in WAT and BAT, TH 
promote lipid mobilisation (lipolysis) and thermoge-
nesis [12, 25].
TH and thermogenesis
In humans, energy expenditure has several compo-
nents, which are generally divided into: obligatory 
thermogenesis or basal metabolism, food-related ther-
mogenesis, thermogenesis related to physical activity, 
and facultative or adaptive thermogenesis [21, 26]. 
Characteristically, for the most part these processes 
involve TH as regulators. Basal metabolism refers to 
the energy used by a resting organism due to essential 
metabolic activities [21]. Thermogenesis associated with 
diet represents 10% of daily energy expenditure and 
occurs due to digestion, absorption, distribution, and 
storage of nutrients. Thermogenesis associated with 
physical activity represents from 50% of total energy 
expenditure in high performance athletes and up to 
10% in sedentary individuals. Facultative thermoge-
nesis occurs in response to cold exposure or a hyper-
caloric diet, and accounts for 10–15% of total energy 
expenditure [27].
The ASNS, when exposed to lower temperature, 
increases the content of noradrenaline in BAT and, 
in synergism with T3, promotes the expression of an 
important protein for thermogenesis that is expressed 
exclusively in brown adipose tissue, the uncoupling 
protein type 1 (UCP1) [22, 24, 25]. UCP1 acts as a regu-
lator in the transport of protons in the mitochondria, 
promoting proton leakage from the intermembranal 
space to the mitochondrial matrix. This leak decreases 
the proton gradient generated between these two mito-
chondrial structures. In this way instead of synthesising 
ATP, the energy dissipates as heat [26].
TH regulate the activity of BAT by endocrine and 
paracrine mechanisms. In this regard, both systemic 
and central nervous system administration of T3 in 
experimental animals has been shown to increase ASNS 
activity, which induces thermogenesis in BAT as well as 
weight loss. Likewise, the inhibition of TH receptors in 
the hypothalamus prevents the activation of thermo-
genesis and consequently leads to weight gain [26–28].
Adrenergic signalling in adipocytes and cardiomyo-
cytes plays a very important role in thermogenesis by 
supplying fatty acids from lipolysis, which are transported 
to BAT through increased blood flow [24, 29]. Interest-
ingly, there is also an increase in the expression of the 
enzyme D2 in BAT, favouring the conversion of T4 to T3, 
thus enhancing thermogenesis [22, 24, 26]. This increase 
in D2 activity is due to stimulation of the ASNS by TH. In 
this way, the thermogenic response induced by cold is 
altered in mice whose D2 expression in BAT is suppressed. 
Likewise, the expression of UCP1 is abolished in mice that 
do not express the TRβ1 isoform in BAT [5, 26]. It has also 
been reported that genetically modified rodents that do 
not express the UCP1 protein lose more than 10°C body 
temperature when exposed lower temperatures [27]. The 
effect of the alteration in adaptive thermogenesis can be 
evidenced by the characteristic cold intolerance presented 
by patients with hypothyroidism.
Obesity
Obesity Epidemic
Obesity is a chronic, low-grade inflammatory and non-
transmissible disease that affects practically all ages 
and is relevant in most countries [30]. The worldwide 
prevalence of obesity in adults was 13% [2]. In Latin 
America, the prevalence of obesity in adults was 23.4%, 
in the most populated countries of the region, Argen-
tina, Brazil, and Mexico, the prevalence of obesity was 
29.4, 19.5, and 32.8%, respectively. On the other hand, 
the global prevalence of obesity in children older than 
five years was 6.7% in 2010 [31]. In Mexico, data from 
2016 showed a prevalence of obesity of 15.3% in chil-
dren between five and 11 years old [32].
Obesity is the result of an imbalance between en-
ergy intake and expenditure. Energy expenditure may 
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be reduced by lack of physical activity, by a reduction 
in basal metabolism, by a decrease in thermogenesis, 
or by the combination of one or more of these factors 
[21, 33, 34].
Comorbidities in patients with obesity may be due 
to extra body weight on the musculoskeletal system 
or by increased secretion of free fatty acids, peptides, 
and adipocytokines produced by adipocytes [35]. As 
complications, the following alterations may be present 
concomitantly or separately: depression, biliary lithiasis, 
hepatic steatosis, dyslipidaemia, arterial hypertension, 
coagulopathies, endothelial dysfunction, thyroid al-
terations, type 2 diabetes mellitus, polycystic ovarian 
syndrome and hypogonadism, breast, oesophagus, 
pancreas, and colon neoplasms, sleep apnoea, and social 
stigma [31, 36, 37].
Obesity as an inflammatory disease
Obesity is recognised as a systemic condition of chronic 
low-grade inflammation, characterised by elevation of 
proinflammatory cytokines and activation of its signal-
ling pathways in various organs, and by accumulation 
of leukocytes in adipose tissue, liver, and other organs 
[29, 38]. Adipose tissue secretes adipocytokines such 
as leptin, adiponectin, resistin, tumour necrosis factor 
alpha (TNF-a), and interleukin type 6 (IL-6) and type 
1beta (IL1-b); capable of modifying the regulation, 
metabolism, and secretion of various hormones [29, 39]. 
When a positive energy balance is established, 
there is an increase in the synthesis and storage of 
fatty acids in the form of triglycerides in adipocytes. 
When WAT approaches the limit of its storage capacity, 
a toxic accumulation of lipids (endotoxaemia) occurs 
in non-adipose tissue, promoting proinflammatory 
mechanisms. At the same time, hypertrophic adipocytes 
undergo necrosis, due to the restriction in the blood 
flow caused by hypertrophy, causing an infiltration of 
leukocytes in white adipose tissue. This type of inflam-
mation has been termed metabolic inflammation or 
metainflammation [29].
The metainflammation may extend to the central 
nervous system; in the hypothalamic inflammation, the 
TNF-a, IL-6, and IL-1b proteins are involved, promot-
ing a state of alteration in the processes that regulates 
energy balance, favouring the development of obesity 
[29, 38]. In hypothalamic inflammation, there is resist-
ance to leptin, which contributes to the adipose tissue 
gain by the loss of anorexigenic mechanisms, as well 
as alterations in the secretion of TRH by hypothalamic 
neurons.
Thyroid dysfunction and obesity
TH participate in both expenditure and energy con-
sumption [26]. In this way, the dysthyroid states are 
associated with weight changes and changes in ther-
mogenesis and basal metabolism. In hypothyroidism, a 
modest weight gain occurs, decreasing thermogenesis 
and basal energy expenditure; contrary events occur 
in hyperthyroidism [35].
Positive correlations have been found between TSH 
levels and body mass index (BMI), suggesting that 
changes in body weight are associated with thyroid 
dysfunction [36, 40–42]. These associations have been 
reported in premenopausal women, children, euthy-
roid adults with obesity, and in patients with morbid 
obesity, excluding causes such as iodine deficiency 
and autoimmune thyroiditis [35]. However, several 
studies have found variable results regarding TSH and 
TH levels in obesity, with both positive and negative 
associations or without any relation [43–47]. In this 
sense, there is still controversy between the relationship 
of thyroid function and BMI, although it is generally 
recognised that in obesity there is an increase in TSH 
and free T3 [41].
Serum levels of leptin have been studied in hypo-
thyroid patients reporting both high and low concen-
trations compared with euthyroid patients [16, 48]. 
Variations are likely to be due to a lack of control of 
variables such as BMI and TH replacement therapy [49]. 
In conditions where there is endogenous obesity, such 
as Prader-Willi syndrome (PWS), some features such as 
short stature, central obesity, and changes in muscle and 
bone mass, which are characteristic of hypothyroidism, 
are also included. In this sense, approximately one-
third of patients with PWS have hypothyroidism. The 
abnormalities presented suggest alterations at the level 
of the hypothalamic-pituitary axis, causing secondary 
hypothyroidism. In this context, obesity is partially 
a consequence of thyroid disorders [50]. Likewise, 
a high prevalence of approximately 20% of hypothy-
roidism and subclinical hypothyroidism has been found 
in individuals with morbid obesity, a number that dou-
bles in relation to what is observed in the general popu-
lation [51]. Another association that is found between 
obesity and the thyroid system is the risk of neoplasias. 
In women, there is a 16% increase in the development 
of differentiated thyroid carcinoma for every 5 kg/m2 
increase in BMI [52]. In this sense, it has been reported 
that small variations in TSH levels, caused by minimal 
changes in T4 dosage during replacement therapy in 
hypothyroid patients, are associated with significant 
changes in resting energy expenditure. These observa-
tions support the clinical evidence that hypothyroidism 
represents a risk factor for the development of over-
weight and obesity [51, 53].
In primary hypothyroidism, altered metabolic 
functions involved in energy expenditure may be 
the primary event, with an ensuing increase in BMI. 
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Subsequently, adipose tissue increases and TSH levels 
rise concomitantly with leptin concentrations [51].
In addition, TSH receptors have been found in pre-
adipocytes and adipocytes, and this signalling pathway 
has been implicated in adipogenesis processes, sug-
gesting that TSH itself may promote adiposity [36, 54]. 
These connections establish a new hypothalamic-pitu-
itary-adipose tissue axis [55, 56]. Under this scenario, 
TH deficiency (hypothyroidism) with the consequent 
increase in TSH could promote weight gain [57, 58].
It is considered that alterations in the regulation of 
TSH secretion may explain the elevated TSH levels in 
patients with obesity. In this regard, D2 activity, the 
main deiodinase at the pituitary level, is key for TSH 
secretion under T3 regulation (negative feedback), and 
it has been observed that in obese patients D2 expres-
sion is decreased. Thus, the recovery of the HPT axis in 
these patients should be the key step in order to restore 
energy expenditure [51]. Other authors suggest that in 
patients with obesity there may be some degree of TH 
resistance due to a reduction in the TR expression [26]. 
In addition, due to the participation of UCPs in 
thermogenesis in different tissues, it is considered that 
the levels of expression and the degree of activity of 
UCPs could have a direct effect in energy expenditure 
and a different predisposition to the accumulation of 
adipose tissue [26]. Facultative thermogenesis, mediated 
by ASNS and T3 within BAT, is diminished in obesity 
models [5]. Notably, simple nucleotide polymorphisms 
associated with obesity have been described in the pro-
moter of the gene encoding UCP1 [59]. Likewise, TRβ 
isoform potentiates the adrenergic effect in WAT for the 
production of free fatty acids (lipolysis) as an energy 
substrate for the generation of heat in BAT. In this rea-
gard, it has been observed that in animal models where 
TRβ is mutated there is accumulation of visceral fat [6].
Another condition associated with obesity is the so-
called endoplasmic reticulum stress, which occurs when 
there is an accumulation of malformed proteins in the 
lumen of such organelle [5, 60]. It has been found that 
D2 activity is rapidly lost in cells that have a stressed 
endoplasmic reticulum [60]. This loss of enzymatic 
activity is accompanied by a state of relative cellular 
hypothyroidism due to the reduction in the cellular 
production of T3 from T4 [5, 60]. In addition, there 
has been an association between a polymorphism of 
nucleotide in the gene coding for D2 with the presence 
of central obesity, arterial hypertension, and diabetes 
mellitus type 2 [5].
Obesity has an influence on the HPT axis feedback 
mechanisms, as shown by the elevation of TSH in 
obese patients, in the absence of thyroid disease [36]. 
Hyperthyrotropinaemia associated with obesity could 
be mediated by a number of factors, for example the 
increase in leptin derived from hypertrophic adipose 
tissue [21]. In this respect, positive correlations between 
leptin and TSH levels support this mechanism [56, 58].
Leptin stimulates the expression of TRH in the arcu-
ate nucleus of the hypothalamus, generating a lower 
expression of hypothalamic TRs, which affects the 
negative feedback system, thus generating disruption 
in the system [55]. As mentioned previously, high levels 
of leptin have been found in adults and children with 
obesity. Likewise, the development of secondary hy-
pothyroidism has been reported in subjects with leptin 
deficiency or resistance [18, 61]. Leptin also regulates 
central and peripheral Ds activity, affecting deiodina-
tion (and therefore the bioactivity) of T4 and T3 [62].
In hyperleptinaemia states, there is an increase 
in TSH, which stimulates the activity of thyroid and 
extrathyroidal D1, increasing free T3 generation and 
the subsequent decrease in free T4 serum levels [19]. 
In this condition, there is also an increase in rT3 serum 
levels, due to deiodination in peripheral tissues such 
as liver and kidney [62, 63]. At the pituitary level, it has 
been found that the administration of leptin inhibits the 
activity of D2, which decreases T3 formation, increas-
ing TSH levels. Thus, it has been proposed that in BAT 
rT3 inhibits D2 post-translationally, which decreases 
the intracellular generation of T3 [64]. This in turn 
could decrease both basal metabolism and facultative 
thermogenesis.
In animal models it has been observed that TSH 
stimulates the secretion of leptin through a direct effect 
on the adipocytes, probably through the TSH receptors 
expressed in this tissue [38, 57, 64].
Figure 3 shows a hypothetical model based in the 
previously discussed information. This model shows 
the possible interaction between the thyroid system 
and obesity, it also shows the processes involved that 
maintain the state of obesity, such as adipogenesis and 
positive energy balance.
It has been shown that the thyroid gland function 
and volume increased in relation to body weight and 
adipocyte mass in premenopausal euthyroid women. 
In addition, a ≥ 10% body weight reduction in obese 
women was found to decrease thyroid volume and 
circulating TSH concentrations [65]. This could be due 
to a decrease in leptin levels due to the reduction of 
WAT, which would subsequently decrease TSH and 
thyroid volume concentrations [56].
A prospective study in euthyroid patients evaluated 
thyroid function with changes in body weight as a risk 
factor predictor for obesity. At six years of follow-up, 
people who were not obese at the beginning of the 
study but who were obese at the end of the study 
showed a significant increase in free T4 and free T3 
levels, compared to those who did not develop obesity 
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during the follow-up [58]. These results suggest that 
elevated TH levels in obese patients are a consequence 
of weight gain rather than the cause of this increase.
The pathogenesis of decreased TH levels in obesity 
has not yet been elucidated, but it is likely that excess 
visceral fat releases cytokines and adipocytokines that 
promote inflammatory mechanisms that interfere with 
the HPT axis. In this context, alterations of the HPT axis 
would be the consequence of the metainflammation 
in states of obesity [36]. On the other hand, the role 
of autoimmunity has become important given the ef-
fect of leptin as a peripheral determinant of immune 
function, including an increase in the activity of Th1 
helper lymphocytes, which are associated with the 
pro-inflammatory response [35, 66, 67].
Levels of anti-thyroperoxidase antibodies, con-
sidered as a marker of autoimmune thyroid disease, 
have been found to be elevated in a group of obese 
patients. In this sense, leptin levels have also been 
positively related to anti-thyroid antibody titres and 
to TSH levels [67]. This suggests that obesity increases 
the susceptibility of developing autoimmune thyroid 
disease, probably through the contribution of leptin in 
the immune system [67–69].
Thyroid volume increases with obesity, and associa-
tions exist between thyroid volume and the presence of 
Figure 3. Hypothetical model of the relation between the thyroidal system and obesity. The mechanisms of the thyroidal system are shown 
in grey. In this model, both the adipogenesis and the positive energy balance favour and/or maintain obesity. Where: TNF-a, tumour 
necrosis factor alpha; IL-6, interleukin 6; IL-1b, interleukin one beta; D2, deiodinase type 2; T3, triiodothyronine, TSH, thyrotropin; 
D1, deiodinase type 1; WAT, white adipose tissue; rT3, reverse triiodothyronine; BAT, brown adipose tissue. The non-continuous line 
shows the effect exerted through the autonomic sympathetic nervous system in BAT
Rycina 3. Hipotetyczny model zależności między układem tarczycy a otyłością. Mechanizmy układu tarczycy przedstawiono kolorem 
szarym. W modelu tym, zarówno adipogeneza, jak i dodatni bilans energetyczny sprzyjają i/lub utrzymują otyłość. TNF-a — czynnik 
martwicy nowotworów alfa; IL-6 — interleukina 6; IL-1b — interleukina 1b; D2 — dejodynaza typu 2; T3 — trójjodotyronina; TSH 
— tyreotropina; D1— dejodynaza typu 1; WAT — biała tkanka tłuszczowa; rT3 — odwrotna trójjodotyronina; BAT — brunatna 
tkanka tłuszczowa. Linia nieciągła przedstawia działanie wywierane przez współczulny autonomiczny układ nerwowy w brunatnej 
tkance tłuszczowej
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autoantibodies [69]. Autoimmune thyroid diseases are 
twice as prevalent in people with obesity compared to 
non-obese people, and slightly more than half of obese 
patients with elevated TSH levels have positive titres 
of anti-thyroid antibodies [67, 70].
Anti-thyroid antibodies may interfere with TH nor-
mal synthesis, thus explaining the decrease in circulat-
ing TH observed in obesity. However, the reversibility 
of TSH circulating levels in some obese patients after 
weight reduction implies that the alterations derived 
from thyroid autoimmunity are not always responsible 
for the elevated TSH levels [68].
Obesity: a cause or consequence  
of thyroid disorders?
Based on information from the publications that have 
studied the associations between thyroid function and 
BMI, the different results support the existence of two 
different scenarios. The first one includes alterations 
in thyroid function as a cause of weight gain, while 
the second considers alterations in thyroid function as 
a consequence of obesity [35, 58].
In the first scenario, hypothyroidism is the initial 
event, with a reduction in basal metabolic expenditure, 
resulting in a positive energy balance associated with 
weight gain. On the other hand, during a decrease in 
TH, the expression of orexigenic peptides decreases, 
favouring a reduction in food consumption [19], thus 
constituting a mechanism that addresses the reduc-
tion of basal energy expenditure to prevent a weight 
increase in hypothyroidism. Because of this, usually 
there is only a moderate weight gain in the hypothyroid 
patient. A higher weight gain is directly related to the 
degree of hypothyroidism, with higher weight gain due 
to a greater severity of thyroid dysfunction. Although 
there is a reduction in caloric intake, the positive energy 
balance predominates because of the large decrease in 
basal energy expenditure [19].
In the second scenario, obesity could be positively 
associated with fluctuations in TH circulating levels 
and the degree of adiposity. The response to the excess 
of adipose tissue is an increase in TH levels, through 
increased secretion of TSH promoted by the increase 
in leptin circulating concentrations generated by the 
adipocytes [51]. Subsequently, with the maintenance 
or increase of adipose tissue, there is a greater degree 
of metainflammation. This causes hypothalamic in-
flammation and alterations in TRH and TSH secretion, 
and interferes with leptin signalling, losing its stimula-
tory effect on the TRH hypothalamic synthesis. These 
mechanisms would then reduce the amounts of circu-
lating TH. As previously mentioned, hyperleptinaemia 
could also condition an acquired thyroid dysfunction, 
through autoimmune phenomena.
Therefore, in the second scenario the reduction in 
TH levels may be due to the phenomena triggered by 
metabolic inflammation, autoimmune events against 
the enzymes necessary for TH synthesis, or a combi-
nation of both. The final effects of the second scenario, 
where obesity is the cause of thyroid disorders, con-
verge towards the first scenario, at the point where 
TH levels are reduced, promoting a positive energy 
balance in obesity.
The variation in the results involving TSH or TH 
determinations in obese patients is possibly due to 
the different degrees and time of evolution of obesity 
presented by individuals at the time of measurement 
[52]. These variables could be equivalent to the severity 
of hypothalamic inflammation or autoimmunity that 
condition thyroid failure.
Conclusions
Because obesity and hypothyroidism are common 
diseases, the possibility of thyroid dysfunction in obese 
patients should be ruled out. Patients with obesity are 
at increased risk of developing thyroid failure, through 
metainflammation and/or autoimmunity.
The presence of elevated TSH circulating concentra-
tions in individuals with obesity does not strictly imply 
a hypothyroid state, but they may be due to adaptive 
mechanisms in the face of the increased adipose tissue. 
In these situations, it is necessary to investigate several 
aspects that condition variations in TSH levels, such as 
the presence of alterations in the TH circulating levels 
and its associated treatment, thyroid autoimmunity 
markers, iodine intake, or drugs that interact negatively 
with the synthesis of TH. In addition, the enzymatic 
deiodination of TH at the peripheral level is a key step 
in the process of regulating the energy balance.
A further benefit on the reduction of adipose tissue 
in obese patients would be the reversibility of alterations 
observed in thyroid function. Likewise, weight loss 
favours significant reductions in circulating concentra-
tions of leptin and TSH. In summary, the relation be-
tween the thyroid system and obesity and overweight 
is complex and involves multiple levels of interaction. 
Perspectives
The development of future thyromimetic drugs seeks 
the selective stimulation of TR, which would allow 
the generation of certain types of effects without the 
secondary complications characteristically associated 
with the stimulation of the other receptor subtypes. 
Also, another field of intense study at the present time 
is the analysis of the factors that induce adipocytes to 
differentiate in BAT, as well as the knowledge of the 
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factors that stimulate the expression of the UCP pro-
teins. This would allow better and personalised treat-
ment in obese patients.
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